Straits Times Index
3,384.55 +3.71 (+0.11%) Nikkei
27,606.46 -79.01 (-0.29%) Hang Seng
21,283.52 -15.18 (-0.07%) FTSE 100
7,900.91 +36.20 (+0.46%) BTC-USD
23,180.54 +266.20 (+1.16%) CMC Crypto 200
534.64 +8.68 (+1.65%)
ABT Feb 2023 130.000 call
| Previous close | 0.0200 |
| Open | 0.0200 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 130.00 |
| Expiry date | 2023-02-17 |
| Day's range | 0.0200 - 0.0200 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
- Motley Fool
Baby Formula Blues Hit Abbott Laboratories Stock Hard in 2022. Can It Rebound in 2023?
Abbott Laboratories (NYSE: ABT) has generally been a good investment to hold over the years. Is Abbott a bad-news buy that could turn things around in 2023, or has this once-safe healthcare stock become too risky of an investment to be holding right now? Last month, Abbott reported its fourth-quarter and year-end results for 2022.
- Motley Fool
Is This Dividend King a Buy for Income Investors?
No matter which way the market goes, the payouts of companies with decades of dividend growth behind them tend to go in one direction: up. Abbott Laboratories' (NYSE: ABT) 50-year dividend growth streak makes it one of just 43 Dividend Kings. With 113,000 employees and a presence in more than 160 countries, Abbott is among the largest healthcare companies in the world.
- Zacks
Ensign Group (ENSG) Shares Down 2% Since Q4 Earnings Release
Ensign Group's (ENSG) fourth-quarter results indicate higher skilled services revenue and improved occupancies, partly offset by the increased cost of services.
